4-(3-Phenyl-4-(3,4,5-trimethoxybenzoyl)-1

Humans Structure-Activity Relationship Drug Resistance, Multiple Wnt Signaling Pathway Drug Resistance, Neoplasm Carbonic Anhydrases / metabolism Carbonic Anhydrase Inhibitors / pharmacology Carbonic Anhydrase IX Molecular Structure Neoplasms Benzenesulfonamides

Journal

Journal of medicinal chemistry
ISSN: 1520-4804
Titre abrégé: J Med Chem
Pays: United States
ID NLM: 9716531

Informations de publication

Date de publication:
09 11 2023
Historique:
medline: 10 11 2023
pubmed: 30 10 2023
entrez: 30 10 2023
Statut: ppublish

Résumé

We synthesized new pyrrole and indole derivatives as human carbonic anhydrase (hCA) inhibitors with the potential to inhibit the Wnt/β-catenin signaling pathway. The presence of both

Identifiants

DOI: 10.1021/acs.jmedchem.3c01424 PMID: 37902628 PMC: PMC10641813
pubmed: 37902628
doi: 10.1021/acs.jmedchem.3c01424
pmc: PMC10641813
doi:

Substances chimiques

Carbonic Anhydrases EC 4.2.1.1
Carbonic Anhydrase Inhibitors 0
Carbonic Anhydrase IX EC 4.2.1.1

Types de publication

Journal Article Research Support, Non-U.S. Gov't Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

14824-14842

Références

Nanomedicine. 2014 Jan;10(1):77-87
pubmed: 23850894
World J Gastroenterol. 2016 Sep 28;22(36):8168-77
pubmed: 27688658
J Natl Cancer Inst. 2015 Mar 11;107(5):
pubmed: 25766403
Expert Opin Drug Discov. 2019 Nov;14(11):1175-1197
pubmed: 31436118
Oncotarget. 2015 Mar 30;6(9):6776-93
pubmed: 25686827
Adv Drug Deliv Rev. 2001 Mar 1;46(1-3):3-26
pubmed: 11259830
Cell Biochem Biophys. 2003;38(1):1-22
pubmed: 12663938
Am J Pathol. 2001 Mar;158(3):905-19
pubmed: 11238039
J Physiol. 2015 Dec 15;593(24):5299-312
pubmed: 26486891
Anal Biochem. 2000 Jun 15;282(1):158-61
pubmed: 10860516
J Med Chem. 2009 Dec 10;52(23):7512-27
pubmed: 19601594
Bioorg Med Chem Lett. 2015 Apr 1;25(7):1385-9
pubmed: 25765908
J Med Chem. 2011 Dec 22;54(24):8394-406
pubmed: 22044164
Int J Mol Sci. 2020 Dec 09;21(24):
pubmed: 33317057
ACS Med Chem Lett. 2017 Apr 26;8(5):521-526
pubmed: 28523104
Cancers (Basel). 2015 Oct 16;7(4):2063-82
pubmed: 26501324
J Med Chem. 2010 Jul 22;53(14):5061-84
pubmed: 20345171
J Med Chem. 2014 Aug 14;57(15):6531-52
pubmed: 25025991
Cancer Lett. 2015 May 1;360(2):219-26
pubmed: 25681670
Oncotarget. 2016 Dec 27;7(52):85861-85875
pubmed: 27811376
Apoptosis. 2002 Aug;7(4):321-8
pubmed: 12101391
J Chem Inf Model. 2014 Aug 25;54(8):2371-9
pubmed: 24931227
Chem Rev. 2012 Aug 8;112(8):4421-68
pubmed: 22607219
Cancer Lett. 2023 Apr 10;559:216120
pubmed: 36893894
J Chem Inf Model. 2021 Aug 23;61(8):3891-3898
pubmed: 34278794
Proc Natl Acad Sci U S A. 2000 Feb 29;97(5):2220-4
pubmed: 10688890
Radiat Oncol. 2010 Nov 01;5:101
pubmed: 21040567
Mol Pharmacol. 1998 Jan;53(1):62-76
pubmed: 9443933
J Med Chem. 2011 Mar 24;54(6):1896-902
pubmed: 21361354
J Comput Aided Mol Des. 2013 Mar;27(3):221-34
pubmed: 23579614
J Comput Chem. 2004 Oct;25(13):1605-12
pubmed: 15264254
J Med Chem. 2002 Jun 6;45(12):2615-23
pubmed: 12036371
J Comput Chem. 2007 Apr 30;28(6):1145-52
pubmed: 17274016
J Comput Chem. 2009 Dec;30(16):2785-91
pubmed: 19399780
J Immunol Methods. 1991 Sep 13;142(2):257-65
pubmed: 1919029
BMC Cancer. 2020 Oct 28;20(1):1038
pubmed: 33115416
J Med Chem. 2011 Jun 9;54(11):3977-81
pubmed: 21506569
J Chem Theory Comput. 2021 Jul 13;17(7):4291-4300
pubmed: 34096718
ACS Med Chem Lett. 2019 Nov 11;11(5):633-637
pubmed: 32435363
Aging (Albany NY). 2016 Oct 10;8(10):2425-2436
pubmed: 27743511
J Med Chem. 2006 Feb 9;49(3):947-54
pubmed: 16451061
Bioorg Med Chem. 2013 Mar 15;21(6):1377-8
pubmed: 23452985
Science. 1997 Mar 21;275(5307):1787-90
pubmed: 9065402
J Med Chem. 2022 Dec 8;65(23):15805-15818
pubmed: 36395526
Neuro Oncol. 2008 Apr;10(2):131-8
pubmed: 18322268
J Med Chem. 2014 Aug 14;57(15):6403-18
pubmed: 25093931
Bioorg Med Chem. 2007 Jul 1;15(13):4336-50
pubmed: 17475500
Methods Mol Biol. 2011;731:237-45
pubmed: 21516412
Proc Natl Acad Sci U S A. 1988 Jun;85(12):4486-90
pubmed: 2898143
Chem Biol Interact. 2020 Apr 1;320:109022
pubmed: 32112862
ACS Med Chem Lett. 2019 Jan 14;10(4):499-503
pubmed: 30996786
J Med Chem. 2012 Aug 9;55(15):6776-83
pubmed: 22775345
Kidney Int. 2007 Jan;71(2):103-15
pubmed: 17164835
Cancer Sci. 2017 Mar;108(3):331-337
pubmed: 28004470
Curr Pharm Des. 2008;14(7):649-54
pubmed: 18336310
Cancer Metastasis Rev. 2009 Dec;28(3-4):335-44
pubmed: 20012924
J Med Chem. 2022 Nov 10;65(21):14655-14672
pubmed: 36269278
J Cheminform. 2011 Oct 07;3:33
pubmed: 21982300
Cold Spring Harb Protoc. 2016 Nov 1;2016(11):
pubmed: 27803251
J Biol Chem. 1971 Apr 25;246(8):2561-73
pubmed: 4994926
Nature. 2004 Mar 11;428(6979):198-202
pubmed: 15014504
Cancer Sci. 2022 Aug;113(8):2642-2653
pubmed: 35723039
Int J Cancer. 2011 Apr 1;128(7):1614-23
pubmed: 20521252
ChemMedChem. 2020 Dec 3;15(23):2264-2268
pubmed: 32946182
Proc Natl Acad Sci U S A. 2009 Aug 18;106(33):13775-9
pubmed: 19666559
J Med Chem. 1995 Oct 13;38(21):4223-33
pubmed: 7473549
Invest New Drugs. 2018 Dec;36(6):1147-1157
pubmed: 30019099
Cancer Res. 2016 Feb 15;76(4):891-901
pubmed: 26645562
Neuro Oncol. 2005 Oct;7(4):465-75
pubmed: 16212811
Science. 1997 Mar 21;275(5307):1784-7
pubmed: 9065401
Br J Cancer. 2020 Jan;122(2):157-167
pubmed: 31819195
Bioorg Med Chem. 2016 Mar 1;24(5):967-75
pubmed: 26822567
Am J Clin Oncol. 2020 Jul;43(7):484-490
pubmed: 32251122
J Med Chem. 2015 Nov 12;58(21):8564-72
pubmed: 26497049
J Med Chem. 2009 Oct 8;52(19):5990-8
pubmed: 19731956

Auteurs

Domiziana Masci (D)

Department of Basic Biotechnological Sciences, Intensivological and Perioperative Clinics, Catholic University of the Sacred Heart, Largo Francesco Vito 1, Rome 00168, Italy.

Michela Puxeddu (M)

Laboratory Affiliated with the Institute Pasteur Italy─Cenci Bolognetti Foundation, Department of Drug Chemistry and Technologies, Sapienza University of Rome, Piazzale Aldo Moro 5, Roma 00185, Italy.

Laura Di Magno (L)

Laboratory Affiliated to Istituto Pasteur Italia─Fondazione Cenci Bolognetti, Department of Molecular Medicine, Sapienza University of Rome, Viale Regina Elena 291, Rome 00161, Italy.

Michele D'Ambrosio (M)

Laboratory Affiliated with the Institute Pasteur Italy─Cenci Bolognetti Foundation, Department of Drug Chemistry and Technologies, Sapienza University of Rome, Piazzale Aldo Moro 5, Roma 00185, Italy.

Anastasia Parisi (A)

Laboratory Affiliated with the Institute Pasteur Italy─Cenci Bolognetti Foundation, Department of Drug Chemistry and Technologies, Sapienza University of Rome, Piazzale Aldo Moro 5, Roma 00185, Italy.

Marianna Nalli (M)

Laboratory Affiliated with the Institute Pasteur Italy─Cenci Bolognetti Foundation, Department of Drug Chemistry and Technologies, Sapienza University of Rome, Piazzale Aldo Moro 5, Roma 00185, Italy.

Ruoli Bai (R)

Molecular Pharmacology Branch, Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, Frederick National Laboratory for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, Maryland 21702, United States.

Antonio Coluccia (A)

Laboratory Affiliated with the Institute Pasteur Italy─Cenci Bolognetti Foundation, Department of Drug Chemistry and Technologies, Sapienza University of Rome, Piazzale Aldo Moro 5, Roma 00185, Italy.
ORCID: 0000-0002-7940-8206

Pietro Sciò (P)

Laboratory Affiliated with the Institute Pasteur Italy─Cenci Bolognetti Foundation, Department of Drug Chemistry and Technologies, Sapienza University of Rome, Piazzale Aldo Moro 5, Roma 00185, Italy.

Viviana Orlando (V)

Department of Biology and Biotechnologies "Charles Darwin", Sapienza University of Rome, Piazzale Aldo Moro 5, Rome 00185, Italy.

Sara D'Angelo (S)

Department of Biology and Biotechnologies "Charles Darwin", Sapienza University of Rome, Piazzale Aldo Moro 5, Rome 00185, Italy.

Stefano Biagioni (S)

Department of Biology and Biotechnologies "Charles Darwin", Sapienza University of Rome, Piazzale Aldo Moro 5, Rome 00185, Italy.

Andrea Urbani (A)

Department of Basic Biotechnological Sciences, Intensivological and Perioperative Clinics, Catholic University of the Sacred Heart, Largo Francesco Vito 1, Rome 00168, Italy.

Ernest Hamel (E)

Molecular Pharmacology Branch, Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, Frederick National Laboratory for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, Maryland 21702, United States.

Alessio Nocentini (A)

Dipartimento Neurofarba, Sezione di Scienze Farmaceutiche e Nutraceutiche, Universitá degli Studi di Firenze, Via Ugo Schiff 6, Sesto Fiorentino I-50019, Firenze, Italy.
ORCID: 0000-0003-3342-702X

Serena Filiberti (S)

Experimental Oncology and Immunology Unit, Department of Molecular and Translational Medicine, University of Brescia, Via Branze 39, Brescia 25123, Italy.

Marta Turati (M)

Experimental Oncology and Immunology Unit, Department of Molecular and Translational Medicine, University of Brescia, Via Branze 39, Brescia 25123, Italy.

Roberto Ronca (R)

Experimental Oncology and Immunology Unit, Department of Molecular and Translational Medicine, University of Brescia, Via Branze 39, Brescia 25123, Italy.

Joanna Kopecka (J)

Department of Oncology and Molecular Biotecnology Center "Guido Tarone″, Oncological Pharmacology Unit, Via Nizza 44, Torino 10126, Italy.

Chiara Riganti (C)

Department of Oncology and Molecular Biotecnology Center "Guido Tarone″, Oncological Pharmacology Unit, Via Nizza 44, Torino 10126, Italy.
ORCID: 0000-0001-9787-4836

Cinzia Fionda (C)

Laboratory Affiliated to Istituto Pasteur Italia─Fondazione Cenci Bolognetti, Department of Molecular Medicine, Sapienza University of Rome, Viale Regina Elena 291, Rome 00161, Italy.

Rosa Bordone (R)

Laboratory Affiliated to Istituto Pasteur Italia─Fondazione Cenci Bolognetti, Department of Molecular Medicine, Sapienza University of Rome, Viale Regina Elena 291, Rome 00161, Italy.

Giorgia Della Rocca (G)

Laboratory Affiliated to Istituto Pasteur Italia─Fondazione Cenci Bolognetti, Department of Molecular Medicine, Sapienza University of Rome, Viale Regina Elena 291, Rome 00161, Italy.

Gianluca Canettieri (G)

Laboratory Affiliated to Istituto Pasteur Italia─Fondazione Cenci Bolognetti, Department of Molecular Medicine, Sapienza University of Rome, Viale Regina Elena 291, Rome 00161, Italy.

Claudiu T Supuran (CT)

Dipartimento Neurofarba, Sezione di Scienze Farmaceutiche e Nutraceutiche, Universitá degli Studi di Firenze, Via Ugo Schiff 6, Sesto Fiorentino I-50019, Firenze, Italy.
ORCID: 0000-0003-4262-0323

Romano Silvestri (R)

Laboratory Affiliated with the Institute Pasteur Italy─Cenci Bolognetti Foundation, Department of Drug Chemistry and Technologies, Sapienza University of Rome, Piazzale Aldo Moro 5, Roma 00185, Italy.
ORCID: 0000-0003-2489-0178

Giuseppe La Regina (G)

Laboratory Affiliated with the Institute Pasteur Italy─Cenci Bolognetti Foundation, Department of Drug Chemistry and Technologies, Sapienza University of Rome, Piazzale Aldo Moro 5, Roma 00185, Italy.
ORCID: 0000-0003-3252-1161

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › 4-(3-Phenyl-4-(3,4,5-trimethoxybenzoyl)-1
questionsmedicales.fr › Phénomènes physiologiques › Phénomènes pharmacologiques et toxicologiques › Phénomènes pharmacologiques › Relation structure-activité › 4-(3-Phenyl-4-(3,4,5-trimethoxybenzoyl)-1
questionsmedicales.fr › Phénomènes physiologiques › Phénomènes pharmacologiques et toxicologiques › Phénomènes pharmacologiques › Résistance aux substances › Multirésistance aux médicaments › 4-(3-Phenyl-4-(3,4,5-trimethoxybenzoyl)-1
questionsmedicales.fr › Phénomènes physiologiques cellulaires › Transduction du signal › Voie de signalisation Wnt › 4-(3-Phenyl-4-(3,4,5-trimethoxybenzoyl)-1
questionsmedicales.fr › Phénomènes physiologiques › Phénomènes pharmacologiques et toxicologiques › Phénomènes pharmacologiques › Résistance aux substances › Résistance aux médicaments antinéoplasiques › 4-(3-Phenyl-4-(3,4,5-trimethoxybenzoyl)-1
questionsmedicales.fr › Enzymes et coenzymes › Enzymes › Lyases › Carbon-oxygen lyases › Hydro-lyases › Carbonic anhydrases › 4-(3-Phenyl-4-(3,4,5-trimethoxybenzoyl)-1
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Mécanismes moléculaires de l'action pharmacologique › Antienzymes › Inhibiteurs de l'anhydrase carbonique › 4-(3-Phenyl-4-(3,4,5-trimethoxybenzoyl)-1
questionsmedicales.fr › Facteurs biologiques › Antigènes › Antigènes néoplasiques › Carbonic anhydrase IX › 4-(3-Phenyl-4-(3,4,5-trimethoxybenzoyl)-1
questionsmedicales.fr › Phénomènes chimiques › Structure moléculaire › 4-(3-Phenyl-4-(3,4,5-trimethoxybenzoyl)-1
questionsmedicales.fr › Tumeurs › 4-(3-Phenyl-4-(3,4,5-trimethoxybenzoyl)-1